Eyepoint Pharmaceuticals (EYPT) News Today $8.92 +0.11 (+1.25%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.78 -0.14 (-1.51%) As of 06/18/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Eyepoint Pharmaceuticals (NASDAQ:EYPT) Coverage Initiated at Royal Bank Of CanadaJune 18 at 2:35 AM | americanbankingnews.comForecasting The Future: 4 Analyst Projections For EyePoint PharmaceuticalsJune 17 at 5:39 PM | benzinga.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - What's Next?June 17 at 12:16 PM | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Royal Bank of CanadaRoyal Bank of Canada began coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday. They set an "outperform" rating and a $28.00 price objective for the company.June 17 at 8:43 AM | marketbeat.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 16 at 7:00 AM | globenewswire.comBrokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $25.38June 14, 2025 | americanbankingnews.comEyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026June 12, 2025 | seekingalpha.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 2.8% - Time to Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 2.8% - Should You Sell?June 11, 2025 | marketbeat.comAnalysts Offer Predictions for EYPT FY2026 EarningsJune 11, 2025 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have received an average recommendation of "Buy" from the nine brokerages that are covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price targJune 11, 2025 | marketbeat.comBrokers Set Expectations for EYPT FY2026 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for EyePoint Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Kim anticipates that the company willJune 10, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Principia Wealth Advisory LLCPrincipia Wealth Advisory LLC boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 97.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 533,778 shares of the company's stock after acquiring an additional 263,396 sJune 7, 2025 | marketbeat.comBreakout Momentum Plays You May Not Know AboutMomentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.June 6, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 9.2% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 9.2% - What's Next?June 4, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Two Sigma Advisers LP cut its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 37.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,500 shares of the companyJune 3, 2025 | marketbeat.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 28.4%EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 7,210,000 shares, a decline of 28.4% from the April 30th total of 10,070,000 shares. Based on an average daily volume of 782,200 shares, the days-to-cover ratio is presently 9.2 days. Approximately 11.1% of the shares of the company are short sold.June 2, 2025 | marketbeat.comTwo Sigma Investments LP Sells 103,098 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Two Sigma Investments LP decreased its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 22.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 353,954 shares of the company's stock after selling 103,098 shares during thJune 1, 2025 | marketbeat.comMillennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Millennium Management LLC bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 446,199 shares of the company's stock, valueJune 1, 2025 | marketbeat.comEyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho SecuritiesMay 31, 2025 | theglobeandmail.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 21.2% - Still a Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 21.2% - Here's WhyMay 30, 2025 | marketbeat.comEyePoint Pharmaceuticals' (EYPT) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday.May 30, 2025 | marketbeat.comBank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Bank of America Corp DE lifted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 648,030 shares of the company's stock after acMay 30, 2025 | marketbeat.comEyePoint Announces Participation at Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comEyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular DegenerationMay 27, 2025 | globenewswire.comWoodline Partners LP Buys 101,724 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Woodline Partners LP grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 501,724 shares of the company's stock after acquiMay 27, 2025 | marketbeat.comDeutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Deutsche Bank AG decreased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 67.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 213,382 shares of the company's stock after sellMay 26, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)BNP Paribas Financial Markets purchased a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 86,809 shares of the company's stock, valued at approximMay 26, 2025 | marketbeat.comNorthern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Northern Trust Corp lifted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 36.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 643,157 shares of the company's stock afterMay 24, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 90.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 857,853 shares of the company's stoMay 22, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for EYPT Q1 Earnings?EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen anticipates that the companMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Acquires 1,607,268 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Suvretta Capital Management LLC boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,783,091 shares of the company's stock afteMay 19, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from BrokeragesEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus rating of "Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a buy rating. The average 1 year price target among brokerages thatMay 19, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Acquired by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC raised its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 211.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,498 shares oMay 17, 2025 | marketbeat.comPatient Square Capital LP Has $10.51 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Patient Square Capital LP boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,410,331 shares of the company's stock after purchasingMay 16, 2025 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comBalyasny Asset Management L.P. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Balyasny Asset Management L.P. raised its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 233.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 223,641 shares of theMay 15, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Laurion Capital Management LPLaurion Capital Management LP lowered its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 55.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 205,578 shares of the company's stock after selling 25May 14, 2025 | marketbeat.comEyePoint Announces Participation at Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comFY2025 EPS Estimates for EYPT Decreased by Cantor FitzgeraldEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of EyePoint Pharmaceuticals in a research report issued on Thursday, May 8th. Cantor Fitzgerald analyst J. Kim now anticipates that the companMay 13, 2025 | marketbeat.comVoya Investment Management LLC Purchases 57,205 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Voya Investment Management LLC raised its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 342.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,914 shares of the company's stock afMay 12, 2025 | marketbeat.comNew Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)May 11, 2025 | finance.yahoo.comEarnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 10, 2025 | uk.finance.yahoo.comChardan Capital Has Lowered Expectations for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock PriceChardan Capital reduced their price objective on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday.May 10, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comAlyeska Investment Group L.P. Buys 100,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Alyeska Investment Group L.P. grew its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 39.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 351,348 shares of the company's stock after acMay 9, 2025 | marketbeat.comBarclays PLC Has $895,000 Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Barclays PLC reduced its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 50.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 120,221 shares of the company's stock after selling 124,824 shares duringMay 8, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comEyePoint Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7, 2025 | seekingalpha.comEyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsMay 7, 2025 | globenewswire.comSusquehanna Fundamental Investments LLC Takes $922,000 Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Susquehanna Fundamental Investments LLC acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 123,769 shares of the company's stock, valued at apprMay 5, 2025 | marketbeat.com Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.440.64▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼84▲EYPT Articles Average Week Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News ALNT News CTKB News LAB News AEHR News SENS News QSI News MASS News QTRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EYPT Stock Free EYPT Stock Alerts